What is Nurix Therapeutics Cash, Cash Equivalents, Marketable Securities?
Nurix Therapeutics's quarterly cash, cash equivalents, marketable securities
increased
from Aug. 2023 ($258.85 Mil) to Nov. 2023 ($287.91 Mil) but then
stayed the same
from Nov. 2023 ($287.91 Mil) to Feb. 2024 ($243.99 Mil).
Nurix Therapeutics's annual cash, cash equivalents, marketable securities
increased
from Nov. 2021 ($295.72 Mil) to Nov. 2022 ($309.14 Mil) but then
declined
from Nov. 2022 ($309.14 Mil) to Nov. 2023 ($287.91 Mil).
Nurix Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data
The historical data trend for Nurix Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Nurix Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 